ZA200202468B - Modulation of T cell differentiation for the treatment of T helper cell mediated diseases. - Google Patents
Modulation of T cell differentiation for the treatment of T helper cell mediated diseases.Info
- Publication number
- ZA200202468B ZA200202468B ZA200202468A ZA200202468A ZA200202468B ZA 200202468 B ZA200202468 B ZA 200202468B ZA 200202468 A ZA200202468 A ZA 200202468A ZA 200202468 A ZA200202468 A ZA 200202468A ZA 200202468 B ZA200202468 B ZA 200202468B
- Authority
- ZA
- South Africa
- Prior art keywords
- modulation
- treatment
- mediated diseases
- cell
- helper
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16054299P | 1999-10-20 | 1999-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200202468B true ZA200202468B (en) | 2003-06-25 |
Family
ID=22577314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200202468A ZA200202468B (en) | 1999-10-20 | 2002-03-27 | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases. |
Country Status (13)
Country | Link |
---|---|
US (3) | US20040234522A1 (xx) |
EP (1) | EP1222209A2 (xx) |
JP (1) | JP4931310B2 (xx) |
KR (3) | KR100840033B1 (xx) |
CN (1) | CN1279054C (xx) |
AU (2) | AU1095001A (xx) |
BR (1) | BR0015055A (xx) |
CA (1) | CA2389317A1 (xx) |
IL (2) | IL148936A0 (xx) |
MX (1) | MXPA02003897A (xx) |
NZ (1) | NZ531141A (xx) |
WO (1) | WO2001029070A2 (xx) |
ZA (1) | ZA200202468B (xx) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02003897A (es) * | 1999-10-20 | 2002-12-13 | Genentech Inc | Modulacion de la diferenciacion de celulas t para el tratamiento de enfermedades mediadas por las celulas t auxiliares. |
US7393532B1 (en) | 2000-10-18 | 2008-07-01 | Genentech, Inc. | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
EP2338910B1 (en) * | 2002-01-18 | 2015-07-08 | ZymoGenetics, Inc. | Cytokine receptor Zcytor17 multimers |
US9738700B2 (en) | 2002-01-18 | 2017-08-22 | Zymogenetics Inc. | ZCYTOR17 heterodimeric cytokine receptor |
WO2004069173A2 (en) * | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
CN1921886A (zh) * | 2004-02-17 | 2007-02-28 | 先灵公司 | 调节细胞因子活性的方法;相关药剂 |
CA2591587A1 (en) * | 2004-12-16 | 2006-06-22 | Genentech, Inc. | Methods for treating autoimmune disorders |
CA2657934C (en) * | 2006-07-19 | 2017-04-04 | The Trustees Of The University Of Pennsylvania | Wsx-1/p28 as a target for anti-inflammatory responses |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5009772A (en) | 1989-02-27 | 1991-04-23 | Kerr-Mcgee Corporation | Solvent extraction process |
DE69008521T2 (de) | 1989-03-07 | 1994-10-20 | Genentech Inc | Kovalente konjugate von lipiden und oligonukleotiden. |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
CA2055435A1 (en) | 1989-05-10 | 1990-11-11 | Eli Gilboa | Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
CA2150262C (en) * | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
WO1997033551A2 (en) | 1996-03-15 | 1997-09-18 | Millennium Pharmaceuticals | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
CA2253942A1 (en) * | 1996-05-10 | 1997-11-20 | Biogen, Inc. | Common gamma chain blocking agents |
US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
MXPA02003897A (es) * | 1999-10-20 | 2002-12-13 | Genentech Inc | Modulacion de la diferenciacion de celulas t para el tratamiento de enfermedades mediadas por las celulas t auxiliares. |
WO2003091424A1 (fr) * | 2002-04-26 | 2003-11-06 | Chugai Seiyaku Kabushiki Kaisha | Procede de criblage d'un anticorps agoniste |
DE60336930D1 (de) * | 2002-12-31 | 2011-06-09 | Schering Corp | IL-27 et IL-2 pour le traitement du cancer |
CA2591587A1 (en) * | 2004-12-16 | 2006-06-22 | Genentech, Inc. | Methods for treating autoimmune disorders |
-
2000
- 2000-10-18 MX MXPA02003897A patent/MXPA02003897A/es active IP Right Grant
- 2000-10-18 CA CA002389317A patent/CA2389317A1/en not_active Abandoned
- 2000-10-18 EP EP00972264A patent/EP1222209A2/en not_active Withdrawn
- 2000-10-18 IL IL14893600A patent/IL148936A0/xx unknown
- 2000-10-18 JP JP2001531868A patent/JP4931310B2/ja not_active Expired - Fee Related
- 2000-10-18 KR KR1020027005032A patent/KR100840033B1/ko not_active IP Right Cessation
- 2000-10-18 AU AU10950/01A patent/AU1095001A/en not_active Abandoned
- 2000-10-18 NZ NZ531141A patent/NZ531141A/en not_active IP Right Cessation
- 2000-10-18 KR KR1020087017088A patent/KR20080068767A/ko not_active Application Discontinuation
- 2000-10-18 BR BR0015055-0A patent/BR0015055A/pt not_active Application Discontinuation
- 2000-10-18 WO PCT/US2000/028827 patent/WO2001029070A2/en active Application Filing
- 2000-10-18 KR KR1020077028670A patent/KR100874280B1/ko not_active IP Right Cessation
- 2000-10-18 CN CNB008171769A patent/CN1279054C/zh not_active Expired - Fee Related
-
2002
- 2002-03-27 IL IL148936A patent/IL148936A/en not_active IP Right Cessation
- 2002-03-27 ZA ZA200202468A patent/ZA200202468B/xx unknown
-
2003
- 2003-09-15 US US10/663,158 patent/US20040234522A1/en not_active Abandoned
-
2006
- 2006-01-27 AU AU2006200374A patent/AU2006200374B2/en not_active Ceased
- 2006-09-29 US US11/537,572 patent/US20070134238A1/en not_active Abandoned
-
2009
- 2009-05-07 US US12/437,452 patent/US20110097325A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1409726A (zh) | 2003-04-09 |
IL148936A0 (en) | 2002-09-12 |
CN1279054C (zh) | 2006-10-11 |
JP4931310B2 (ja) | 2012-05-16 |
US20110097325A1 (en) | 2011-04-28 |
WO2001029070A2 (en) | 2001-04-26 |
WO2001029070A8 (en) | 2001-09-20 |
NZ531141A (en) | 2005-07-29 |
AU2006200374A1 (en) | 2006-02-23 |
BR0015055A (pt) | 2002-07-16 |
CA2389317A1 (en) | 2001-04-26 |
KR20070121855A (ko) | 2007-12-27 |
KR100874280B1 (ko) | 2008-12-18 |
PL355284A1 (en) | 2004-04-05 |
KR100840033B1 (ko) | 2008-06-19 |
IL148936A (en) | 2010-12-30 |
AU1095001A (en) | 2001-04-30 |
US20070134238A1 (en) | 2007-06-14 |
KR20080068767A (ko) | 2008-07-23 |
EP1222209A2 (en) | 2002-07-17 |
US20040234522A1 (en) | 2004-11-25 |
AU2006200374B2 (en) | 2009-12-10 |
KR20020048971A (ko) | 2002-06-24 |
JP2003512824A (ja) | 2003-04-08 |
WO2001029070A3 (en) | 2002-05-02 |
MXPA02003897A (es) | 2002-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AUPQ302899A0 (en) | Implants for the use in the treatment of aneurysmal disease | |
AU3673499A (en) | Hydrogel for the therapeutic treatment of aneurysms | |
AU7842500A (en) | System for orthopedic treatment | |
EP1031830B8 (fr) | Système électrochimique pour la détermination d'un temps de coagulation du sang | |
HK1031201A1 (en) | Mixing/charging port for medical treatment. | |
IL144378A0 (en) | Platform for the differentiation of cells | |
AU6910600A (en) | Methods for the treatment of mental disorders | |
AU7622000A (en) | Compounds for the treatment of viral-mediated diseases | |
AU5215300A (en) | Dental treatment area | |
ZA973622B (en) | Use of forms of hyaluronic acid (HA) for the treatment of cancer. | |
HUP0200738A3 (en) | Method of the treatment of incontinence | |
HUP0104963A3 (en) | Compositions for the treatment of skin diseases | |
ZA200202468B (en) | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases. | |
AU4770800A (en) | Body treatment product | |
AU2021601A (en) | Composition for the treatment of dandruff | |
AU1878201A (en) | Composition for the treatment of damaged tissue | |
HK1038510A1 (en) | Use of neurotrophic factor stimulators for the treamtent of ophthalmic neurodegenerative diseases. | |
AU4556800A (en) | Novel treatment | |
AU3004000A (en) | Methods for the treatment of apolipoprotein e related diseases | |
ZA200110539B (en) | Oxazinocarbazoles for the treatment of CNS diseases. | |
PL347976A1 (en) | Isonipecotamides for the treatment of integrin−mediated disorders | |
IL135994A0 (en) | Combination therapy for the treatment of aids | |
MXPA03004454A (es) | Derivados de imidazolona para el tratamiento de enfermedades virales. | |
AU1405001A (en) | Treatment of diseases | |
AU6016499A (en) | Medical treatment trolley |